The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

In 1987, fewer than one in five American adults were obese, and by 1999, obesity was responsible for more than 300,000 excess ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

Why Kirk Spano sees Pfizer as one of the next big winners from AI and why he thinks investors should be selling cash secured ...

A judge who is married to a former Pfizer executive is overseeing Mangione’s federal pretrial hearings. But she won’t oversee ...

"Federal law requires defendants to ensure that their drug labels remain accurate, and when new scientific information ...

Pfizer trades at a 21.7% discount to peers on a 1-yr forward P/E basis, which is a point for the bullish arguments. Find out ...